The PRISMAP project


PRISMAP -  The Euro­pean medi­cal iso­tope pro­gramme: Pro­duc­tion of high purity iso­to­pes by mass sepa­ra­tion.

PRISMAP is the Euro­pean medi­cal radio­nuc­lide pro­gramme on the pro­duc­tion of high purity radio­nuc­li­des (radio­ac­tive iso­topes) by mass sepa­ra­tion. It creates the Euro­pean con­sor­tium of the key intense neu­tron sour­ces, iso­tope mass sepa­ra­tion faci­li­ties and high-power acce­le­ra­tors and cyc­lo­trons, with leading biomedi­cal and heal­th­care rese­arch insti­tu­tes in the active trans­la­tion of the emer­ging radio­nuc­li­des into medi­cal dia­gno­sis and tre­at­ment.

PRISMAP goal is to cre­ate a sin­gle-entry point for a frag­men­ted user com­mu­nity distri­bu­ted amongst uni­ver­si­ties, rese­arch cen­ters, indu­stry and hospi­tals, in a simi­lar way as how the Natio­nal Iso­tope Deve­lop­ment Cen­ter NIDC, sup­ported by the Depart­ment of Energy (DOE), has pro­vi­ded radio­nuc­lide sour­ces for users in the USA.

PRISMAP brings toge­ther a con­sor­tium of 23 bene­fi­cia­ries from 13 coun­tries, one Euro­pean Rese­arch Labo­ra­tory and an Inter­na­tio­nal Orga­ni­sa­tion. It rece­ives the sup­port of leading asso­cia­tions and insti­tu­tions in the field such as the Euro­pean Asso­cia­tion of Nuc­lear Medi­cine (EANM) and the Inter­na­tio­nal Ato­mic Energy Agency (IAEA).

Mapa konsorcjantów


Project goals:

The project goal is to pro­vide a susta­ina­ble source of high purity grade new radio­nuc­li­des for medi­cine, invo­lving from the onset upco­ming major Euro­pean infra­struc­tu­res, to pro­vide a sin­gle-entry point for all rese­archers active in this field inc­lu­ding SMEs, glo­bal pharma, nuc­lear cen­tres, hospi­tals and uni­ver­si­ties, using stan­dardized access pro­ce­du­res.

The new iso­tope enrich­ment and stan­dardization tech­ni­ques trig­ge­red in PRISMAP will expand its servi­ces and pro­vide them to yet unre­acha­ble remote Euro­pean labo­ra­to­ries. PRISMAP thus stri­ves to cre­ate a para­digm shift in the early phase rese­arch on radio­phar­ma­ceu­ti­cals, targeted drugs for can­cer – one of the major dise­ases in Europe – the­ra­no­stics and per­so­na­li­sed medi­cine, sha­ping the Euro­pean iso­tope land­mark as a gold stan­dard to acce­le­rate the deve­lop­ment of the pharma indu­stry and ulti­ma­tely of bet­ter heal­th­care for the impro­ve­ment of humans life.

Project objectives:

▪Pro­vide access to new radio­nuc­lides and new purity gra­des for the medi­cal rese­arch;
▪Cre­ate a com­mon entry port and web inter­face to the star­ting rese­arch com­mu­nity;
▪En­hance the cla­rity and regu­la­tory pro­ce­du­res to enhance rese­arch with radio­phar­ma­ceu­ti­cals;
▪Im­prove the deli­ve­red radio­nuc­lide data and regu­la­tion, along with bio­me­di­cal rese­arch capa­city;
▪En­sure susta­ina­bi­lity of PRISMAP on the long term;
Nota­bly, PRISMAP addres­ses can­cer which is a major socie­tal chal­lenge as recen­tly recon­fir­med by Europe’s Beating Can­cer Plan.

projekt PRISMAP mapa działania


Duration: 1 May 2021 r. – 30 April 2025 r. (48 months)

Funded under: European Union's Horizon 2020 research and innovation programme     

EU contribution: 4 995 257,50 EUR

NCBJ contribution: 321 125,00 EUR

The coordinator of the project: prof. Renata Mikołajczak

Project website: www.pri­

Logo projektu PRISMAP           Logo UE

Logo projektu PRISMAP
Mapa konsorcjantów
projekt PRISMAP mapa działania
Logo UE